What is Amplion?
Founded in 2013 and headquartered in Bend, Oregon, Amplion operates at the intersection of biotechnology and advanced data analytics. The company provides a sophisticated platform designed to deliver evidence-based intelligence, enabling science teams to execute strategic decisions with greater precision. Its core offerings support a wide array of critical functions, including drug discovery, clinical development, and the advancement of companion diagnostics.
By synthesizing vast amounts of complex scientific data into actionable insights, Amplion empowers researchers and pharmaceutical leaders to mitigate risk and accelerate time-to-market for life-saving therapies. The platform serves as a foundational tool for organizations aiming to maintain a competitive edge in the rapidly evolving field of precision medicine, where data accuracy and strategic foresight are paramount.
How much funding has Amplion raised?
Amplion has raised a total of $1.7M across 3 funding rounds:
Angel/Seed
$1M
Debt
$350K
Debt
$368K
Angel/Seed (2014): $1M with participation from Seven Peaks Ventures
Debt (2020): $350K led by PPP
Debt (2021): $368K supported by PPP
Key Investors in Amplion
Seven Peaks Ventures
Seven Peaks Ventures partners with entrepreneurs to build and scale disruptive, category-leading businesses across various sectors including AI, robotics, space technology, renewable energy, blockchain-enabled DeFi, and cyber-security.
PPP
Public-Private Partnership
What's next for Amplion?
With the recent influx of capital, Amplion is well-positioned to scale its enterprise-level operations and enhance its technological capabilities. The strategic focus will likely shift toward expanding the platform's analytical depth and broadening its reach within the global pharmaceutical and biotech ecosystems. As the company matures, it is expected to prioritize the integration of emerging AI-driven methodologies to further refine its intelligence offerings.
The path forward involves not only maintaining its current market leadership but also exploring new frontiers in companion diagnostics and personalized medicine. By continuing to align its product roadmap with the evolving needs of the scientific community, Amplion is poised to remain a pivotal player in the digital transformation of drug development and clinical research.
